Joseph Larmarange1,2 Joanna Orne-Gliemann3 Collins Iwuji1 John Imrie1,4 France Lert5 François Dabis3 Marie-Louise Newell1,6 for the ANRS 12249 TasP Study Group
- Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa.
- Centre Population et Développement (CEPED UMR 196 Université Paris Descartes Ined IRD), France.
- INSERM / University of Bordeaux Segalen, ISPED, Centre Inserm U897- Épidemiologie-Biostatistique, France.
- Centre for Sexual Health and HIV Research, University College of London, United Kingdom.
- CESP (Inserm Unité 1018), Villejuif, France.
- Faculty of Medicine, University of Southampton, United Kingdom.
The ANRS 12249 Treatment as Prevention (TasP) trial is assessing whether HIV testing of all members of a community, followed by immediate ART initiation of all HIV-infected individuals, regardless of immunological or clinical staging, will prevent onward sexual transmission and reduce HIV incidence in the same population. The implementation of universal and repeat home-based HIV testing is not documented yet in a high HIV incidence and prevalence context.
A cluster-randomised trial is implemented using a phased-approach in the Hlabisa sub-district (KwaZulu Natal, South Africa) where more than 20% of adults are living with HIV. The trial started in March 2012; ten clusters are implemented in the first phase to assess the feasibility and acceptability of the two consecutive interventions (test then treat). The HIV testing strategy consists in a large range of community and clinic HIV testing options including the implementation of 6-monthly rounds of home-based HIV counselling and testing by dedicated counsellors. At each home visit, trial participants are administered individual questionnaires and offered a rapid HIV test.
As of April 30, 2013, 6 907 eligible subjects (16 years or above) were registered in six clusters and 5 122 (74%) were contacted. HIV status of 3 923 (76.5% of those contacted) was ascertained, 3 256 accepting the rapid HIV test at home and 667 being already aware of their HIV-positive status. We will present updated data from the first four trial clusters, where all eligible members of the community will have been offered three rounds of home-based HIV testing within 18 months. Uptake of HIV testing at each round will be reported. Uptake of repeat HIV testing will be measured among those testing HIV-negative at first round and who accept repeat HIV testing at rounds 2 and 3. We will also describe the reasons for HIV test refusal. Finally, we will present participants’ attitudes regarding repeat HIV testing, and changes between rounds 1 and 3.
Acceptance of regular and frequent HIV testing is key to the community-based efficacy of treatment as prevention initiatives in settings with very high incidence. Our data will provide first indications of whether repeat home-based HIV testing is acceptable and feasible in such a rural South African region.
Larmarange Joseph, Orne-Gliemann Joanna, Iwuji Collins, Imrie John, Lert France, Dabis François, Newell Marie-Louise and ANRS 12249 TasP Study Group (2013) “Acceptability and Uptake of Repeat Home-based HIV Counselling and Testing in Rural South Africa. Preliminary Data of the ANRS 12249 TasP Trial” (poster n°2406992), presented at the 17th International Conference on AIDS and STIs in Africa (ICASA), Cape Town.